UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Real-World Healthcare Resource Utilization and Cost Burden Assessment for Adults With Generalized Myasthenia Gravis in the United States

Frontiers in neurology, 2022-01, Vol.12, p.809999-809999

2022

Volltextzugriff (PDF)

Discussion of “Theoretical Analysis of Wing Dike Impact on River Flood Stages” by Fredrik Huthoff, Nicholas Pinter, and Jonathan W. F. Remo

Journal of hydraulic engineering (New York, N.Y.), 2014-11, Vol.140 (11)

2014

Volltextzugriff (PDF)

Efgartigimod Demonstrates Consistent Improvements in Generalized Myasthenia Gravis Patients of Shorter Disease Duration (P1-5.015)

Neurology, 2023-04, Vol.100 (17_supplement_2)

2023

Volltextzugriff (PDF)

Efgartigimod demonstrates consistent improvements in patients with generalized myasthenia gravis of shorter disease duration

Journal of the neurological sciences, 2023-12, Vol.455, p.121088, Article 121088

2023

Volltextzugriff (PDF)

Achievement of Minimal Symptom Expression and Effect on Disease-specific Measures in Acetylcholine Receptor Antibody-positive Participants with Generalized Myasthenia Gravis Treated with Efgartigimod in ADAPT/ADAPT+ (P10-11.009)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

Real-World Utilization Patterns of Intravenous Immunoglobulin in Adults With Generalized Myasthenia Gravis in the United States

Neurology, 2022-12, Vol.99 (23_Supplement_2)

2022

Volltextzugriff (PDF)

Numbers Needed to Treat and Costs Per Improved Outcome Among Treatments for Myasthenia Gravis

Neurology, 2022-12, Vol.99 (23_Supplement_2)

2022

Volltextzugriff (PDF)

Fixed-cycle and Continuous Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Study Design of ADAPT NXT (P10-11.010)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

Post-hoc analyses from the ADAPT clinical study demonstrate aggregate sustained benefit of Efgartigimod in generalized myasthenia gravis

Journal of the neurological sciences, 2024-10, Vol.466, p.123264, Article 123264

2024

Volltextzugriff (PDF)

Fixed Cycle and Q2W Dosing of Intravenous Efgartigimod for gMG: Part A of ADAPT NXT

Neurology, 2024-10, Vol.103 (7_Supplement_1)

2024

Volltextzugriff (PDF)

Efgartigimod demonstrates consistent improvements in patients with generalized myasthenia gravis regardless of prior treatment failures

Journal of the neurological sciences, 2023-12, Vol.455, p.121094, Article 121094

2023

Volltextzugriff (PDF)

Long-term Safety and Efficacy of Efgartigimod in Patients With Generalized Myasthenia Gravis: Interim Results of the ADAPT+ Study

Neurology, 2022-12, Vol.99 (23_Supplement_2)

2022

Volltextzugriff (PDF)

Risk–Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia Gravis

Advances in therapy, 2024-10, Vol.41 (12), p.4628-4647

2024

Volltextzugriff (PDF)

Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study

European journal of neurology, 2024-01, Vol.31 (1), p.e16098-n/a

2024

Volltextzugriff (PDF)

Practice patterns in the management of myasthenia gravis: a cross-sectional survey of neurologists in the United States

RRNMF Neuromuscular Journal, 2021-12, Vol.2 (5)

2021

Volltextzugriff (PDF)

The photoperiod control of coho salmon smoltification

Aquaculture, 1982-01, Vol.28 (1), p.105-111

Brauer, Edward P.

1982

Volltextzugriff (PDF)

A mechanical volumetric feeding device for aquaculture research

Aquaculture, 1979-01, Vol.17 (1), p.69-71

1979

Volltextzugriff (PDF)

In silico tools for accurate HLA and KIR inference from clinical sequencing data empower immunogenetics on individual-patient and population scales

Briefings in bioinformatics, 2021-05, Vol.22 (3)

2021

Volltextzugriff (PDF)

A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo

PloS one, 2018-01, Vol.13 (1), p.e0191046-e0191046

2018

Volltextzugriff (PDF)

T-cell receptor β-selection is required at the CD4+CD8+ stage of human T-cell development

The Journal of immunology (1950), 2021-05, Vol.206 (10), p.2271-2276

2021

Volltextzugriff (PDF)

Advances in multiangle satellite remote sensing of speciated airborne particulate matter and association with adverse health effects: from MISR to MAIA

Journal of applied remote sensing, 2018-10, Vol.12 (4), p.1

2018

Volltextzugriff (PDF)

Abstract P4-06-01: Using multi-omic profiling to unravel the complexity of triple-negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P4-P4-06-01

2020

Volltextzugriff (PDF)

Holocene environmental variability—the record from Lago Grande di Monticchio, Italy

Quaternary international, 2002-01, Vol.88 (1), p.69-80

2002

Volltextzugriff (PDF)

Electronic and structural characterization of LiF tunnel barriers in organic spin-valve structures

Journal of applied physics, 2011-04, Vol.109 (7), p.07C509-07C509-3

2011

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(30)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Real-World Healthcare Resource Utilization and Cost Burden Assessment for Adults With Generalized Myasthenia Gravis in the United States

Discussion of “Theoretical Analysis of Wing Dike Impact on River Flood Stages” by Fredrik Huthoff, Nicholas Pinter, and Jonathan W. F. Remo

Efgartigimod Demonstrates Consistent Improvements in Generalized Myasthenia Gravis Patients of Shorter Disease Duration (P1-5.015)

Efgartigimod demonstrates consistent improvements in patients with generalized myasthenia gravis of shorter disease duration

Achievement of Minimal Symptom Expression and Effect on Disease-specific Measures in Acetylcholine Receptor Antibody-positive Participants with Generalized Myasthenia Gravis Treated with Efgartigimod in ADAPT/ADAPT+ (P10-11.009)

Real-World Utilization Patterns of Intravenous Immunoglobulin in Adults With Generalized Myasthenia Gravis in the United States

Numbers Needed to Treat and Costs Per Improved Outcome Among Treatments for Myasthenia Gravis

Fixed-cycle and Continuous Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Study Design of ADAPT NXT (P10-11.010)

Post-hoc analyses from the ADAPT clinical study demonstrate aggregate sustained benefit of Efgartigimod in generalized myasthenia gravis

Fixed Cycle and Q2W Dosing of Intravenous Efgartigimod for gMG: Part A of ADAPT NXT

Efgartigimod demonstrates consistent improvements in patients with generalized myasthenia gravis regardless of prior treatment failures

Long-term Safety and Efficacy of Efgartigimod in Patients With Generalized Myasthenia Gravis: Interim Results of the ADAPT+ Study

Risk–Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia Gravis

Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study

Practice patterns in the management of myasthenia gravis: a cross-sectional survey of neurologists in the United States

The photoperiod control of coho salmon smoltification

A mechanical volumetric feeding device for aquaculture research

In silico tools for accurate HLA and KIR inference from clinical sequencing data empower immunogenetics on individual-patient and population scales

A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo

T-cell receptor β-selection is required at the CD4+CD8+ stage of human T-cell development

Advances in multiangle satellite remote sensing of speciated airborne particulate matter and association with adverse health effects: from MISR to MAIA

Abstract P4-06-01: Using multi-omic profiling to unravel the complexity of triple-negative breast cancer (TNBC)

Holocene environmental variability—the record from Lago Grande di Monticchio, Italy

Cross-Regional Data Initiative for the Assessment and Development of Treatment for Neurological and Mental Disorders

Electronic and structural characterization of LiF tunnel barriers in organic spin-valve structures

Aktive Filter

Suchergebnisse filtern